IMpower010: Phase III Study of Atezolizumab vs BSC After Adjuvant Chemotherapy in Patients with Completely Resected NSCLC

被引：3
|
作者：
Vallieres, Eric [1 ]
Felip, Enriqueta [2 ]
Altorki, Nasser [3 ]
Zhou, Caicun [4 ]
Zuo, Yunxia [5 ]
Howland, Michael [6 ]
Xia, Fan [5 ]
Hoang, Tien [6 ]
Sandler, Alan [6 ]
Wakelee, Heather [7 ]
机构：
[1] Swedish Canc Inst, Seattle, WA USA
[2] Vall dHebron Univ Hosp, Barcelona, Spain
[3] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA
[4] Tongji Univ, Affiliated Shanghai Pulm Hosp, Shanghai, Peoples R China
[5] Roche China Holding Ltd, Shanghai, Peoples R China
[6] Genentech Inc, San Francisco, CA 94080 USA
[7] Stanford Canc Inst, Stanford, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2016年 / 11卷 / 11期
关键词：
D O I：
10.1016/j.jtho.2016.09.090
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS01.55
引用
收藏
页码：S304 / S304
页数：1
相关论文
共 50 条
  • [31] Feasibility Study of Adjuvant Chemotherapy with Carboplatin and Nab-Paclitaxel for Completely Resected NSCLC
    Katsurada, Naoko
    Tachihara, Motoko
    Hatakeyama, Yukihisa
    Koyama, Kiyoko
    Yumura, Masako
    Kiriu, Tatsunori
    Dokuni, Ryota
    Hazama, Daisuke
    Tokunaga, Shuntaro
    Tamura, Daisuke
    Nakata, Kyosuke
    Yamamoto, Masatsugu
    Kamiryo, Hiroshi
    Kobayashi, Kazuyuki
    Tanaka, Yugo
    Maniwa, Yoshimasa
    Nishimura, Yoshihiro
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 777 - 782
  • [32] A phase II study of gemcitabine plus carboplatin as adjuvant chemotherapy in patients with resected NSCLC
    Yoshino, Reiko
    Tomizawa, Yoshio
    Takei, Kousuke
    Tomizawa, Mai
    Yoshii, Akihiro
    Kawashima, Osamu
    Watanabe, Satoru
    Hisada, Takeshi
    Saitou, Ryusei
    Yamada, Masanobu
    ANNALS OF ONCOLOGY, 2015, 26 : 98 - 98
  • [33] IMpower151: Phase III Study of Atezolizumab plus Bevacizumab plus Chemotherapy in 1L Metastatic Nonsquamous NSCLC
    Zhou, C.
    Dong, X.
    Chen, G.
    Wang, Z.
    Wu, X.
    Yao, Y.
    Zhang, Y.
    Cheng, Y.
    Pan, H.
    Zhang, X.
    Cui, J.
    Wang, L.
    Chen, X.
    Li, X.
    Wang, Z.
    Wang, Q.
    He, J.
    Wang, M.
    Yan, I.
    Qian, L.
    An, A.
    Cai, A.
    Wu, Q.
    Ballinger, M.
    Wang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S64 - S65
  • [34] Patient-reported outcomes (PROs) in the randomized, phase III IMpower110 study of atezolizumab (atezo) vs chemotherapy in 1L metastatic NSCLC.
    de Marinis, Filippo
    Giaccone, Giuseppe
    Herbst, Roy S.
    Oprean, Cristina-Marinela
    Szczesna, Aleksandra
    Boukovinas, Ioannis
    Bonomi, Lucia
    Kim, Young-Chul
    Summers, Yvonne J.
    Kurata, Takayasu
    Komatsubara, Kimberly Mayumi
    Chen, Megan
    Deng, Yu
    Kuriki, Hiroshi
    Mocci, Simonetta
    Phan, See
    Jassem, Jacek
    Spigel, David R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] IMpower030: Phase III Study Evaluating Neoadjuvant Treatment of Resectable Stage II-IIIB NSCLC with Atezolizumab plus Chemotherapy
    Rizvi, N.
    Gandara, D.
    Solomon, B.
    Kim, A.
    Brunelli, A.
    Sun, S.
    Gitlitz, B.
    Tajima, K.
    Lin, W.
    Sandler, A.
    Peters, S.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S863 - S863
  • [36] Adjuvant chemotherapy in completely resected gastric cancer: A Randomized phase III trial conducted by GOIRC
    Di Costanzo, Francesco
    Gasperoni, Silvia
    Manzione, Luigi
    Bisagni, Giancarlo
    Labianca, Roberto
    Bravi, Stefano
    Cortesi, Enrico
    Carlini, Paolo
    Bracci, Raffaella
    Tomao, Silverio
    Messerini, Luca
    Arcangeli, Annarosa
    Torri, Valter
    Bilancia, Domenico
    Floriani, Irene
    Tonato, Maurizio
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (06): : 388 - 398
  • [37] A Phase III Study of Adjuvant Chemotherapy in Patients with Completely Resected, Node-Negative Non-Small Cell Lung Cancer
    Kunitoh, H.
    Sakurai, H.
    Tsuboi, M.
    Wakabayashi, M.
    Okada, M.
    Suzuki, K.
    Ikeda, N.
    Takahama, M.
    Takenoyama, M.
    Ohde, Y.
    Yoshiya, K.
    Matsumoto, I.
    Yamashita, M.
    Marutsuka, T.
    Date, H.
    Hasumi, T.
    Yamashita, Y.
    Okumura, N.
    Watanabe, S.
    Asamura, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S270 - S271
  • [38] Influence of adjuvant chemotherapy on survival for patients with completely resected high-risk stage IB NSCLC
    Shen, Zi-Qing
    Feng, Kun-Peng
    Fang, Zi-Yao
    Xia, Tian
    Pan, Shu
    Ding, Cheng
    Xu, Chun
    Ju, Sheng
    Chen, Jun
    Li, Chang
    Zhao, Jun
    JOURNAL OF CARDIOTHORACIC SURGERY, 2024, 19 (01)
  • [39] Influence of adjuvant chemotherapy on survival for patients with completely resected high-risk stage IB NSCLC
    Zi-Qing Shen
    Kun-Peng Feng
    Zi-Yao Fang
    Tian Xia
    Shu Pan
    Cheng Ding
    Chun Xu
    Sheng Ju
    Jun Chen
    Chang Li
    Jun Zhao
    Journal of Cardiothoracic Surgery, 19
  • [40] IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1-Selected Chemotherapy Naive NSCLC Patients
    Herbst, Roy S.
    De Marinis, Filippo
    Jassem, Jacek
    Lam, Sivuonthanh
    Mocci, Simonetta
    Sandler, Alan
    Lopez-Chavez, Ariel
    Deng, Yu
    Giaccone, Giuseppe
    Spigel, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S304 - S305
12345